Literature DB >> 17944888

Disruption of tissue-type plasminogen activator gene in mice aggravated liver fibrosis.

Yao Hsiao1, Tie Zou, Chang-Chun Ling, Hua Hu, Xian-Mei Tao, Hou-Yan Song.   

Abstract

BACKGROUND AND AIM: Tissue-type plasminogen activator (tPA) is one of the major components in the matrix proteolytic network whose role in the pathogenesis of liver fibrosis remains unknown. The aim of this study is to investigate the role of tPA in carbon tetrachloride (CCl(4))-induced liver fibrosis.
METHODS: Wild-type and tPA knockout mice (8 mice per group) were injected interperitoneumly with 25% CCl(4) 2 ml/kg twice per week as CCl(4) administration groups and olive oil 2 ml/kg as controls. After 4 weeks, the livers of mice were removed under deep anesthesia and prepared for further studies such as histology, immunostaining, hydroxyproline assay, zymography and western blot analysis.
RESULTS: Mice lacking tPA developed more severe morphological injury and displayed an increased deposition of collagen in the liver after CCl(4) administration compared with wild-type counterparts. Deficiency of tPA increased alpha-smooth muscle actin expression in the mice livers. On the other hand, the decrease of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) activities, metalloproteinase-13 (MMP-13) expression and a marked increase of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) expression were found in the liver of CCl(4) administrated tPA(-/-) mice compared with wild-type counterparts.
CONCLUSIONS: Deficiency of tPA aggravated liver fibrosis through promoting hepatic stellate cells (HSCs) activation and inhibiting ECM degradation by decreasing MMP-2, MMP-9 activities and disrupting the balance between MMP-13 and TIMP-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944888     DOI: 10.1111/j.1440-1746.2007.05100.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

1.  Specific shRNA targeting of FAK influenced collagen metabolism in rat hepatic stellate cells.

Authors:  Zhi-Na Dun; Xiao-Lan Zhang; Jun-Yan An; Li-Bo Zheng; Robert Barrett; Shu-Rui Xie
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 2.  Animal models for the study of liver fibrosis: new insights from knockout mouse models.

Authors:  Hiromitsu Hayashi; Takao Sakai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

Review 3.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

4.  Retina Is Protected by Neuroserpin from Ischemic/Reperfusion-Induced Injury Independent of Tissue-Type Plasminogen Activator.

Authors:  R P Gu; L L Fu; C H Jiang; Y F Xu; X Wang; J Yu
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 5.  Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis.

Authors:  Takaoki Saneyasu; Riaz Akhtar; Takao Sakai
Journal:  Biomed Res Int       Date:  2016-10-09       Impact factor: 3.411

6.  Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.

Authors:  Yan Hu; Arturo O Barron; Sofya Gindina; Sandeep Kumar; Shravan Chintala; Ashima Nayyar; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-04-01       Impact factor: 4.925

7.  Tissue-type plasminogen activator suppresses activated stellate cells through low-density lipoprotein receptor-related protein 1.

Authors:  Liang-I Kang; Kumiko Isse; Kelly Koral; William C Bowen; Selen Muratoglu; Dudley K Strickland; George K Michalopoulos; Wendy M Mars
Journal:  Lab Invest       Date:  2015-08-03       Impact factor: 5.662

8.  Tissue plasminogen activator in trabecular meshwork attenuates steroid induced outflow resistance in mice.

Authors:  Sandeep Kumar; Shaily Shah; Hai Michael Tang; Matthew Smith; Teresa Borrás; John Danias
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.